

# Christopher I Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919714/publications.pdf>

Version: 2024-02-01

145  
papers

9,532  
citations

47006

47  
h-index

40979

93  
g-index

152  
all docs

152  
docs citations

152  
times ranked

11309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested caseâ€“control study. <i>Cancer Causes and Control</i> , 2022, 33, 593.	1.8	1
2	Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 477-484.	2.5	2
3	Higher vitamin B6 status is associated with improved survival among patients with stage Iâ€“III colorectal cancer. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 303-313.	4.7	2
4	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. <i>Breast Cancer Research</i> , 2022, 24, 27.	5.0	15
5	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1068-1076.	2.5	1
6	Disparities in risk of advanced stage liver cancer and mortality by race and ethnicity. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	0
7	Presurgery Adhesion Molecules and Angiogenesis Biomarkers Are Differently Associated with Outcomes in Colon and Rectal Cancer: Results from the ColoCare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1650-1660.	2.5	5
8	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6.	1.3	36
9	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1490-1502.	4.7	27
10	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	12.1	44
11	Circulating B-vitamin biomarkers and B-vitamin supplement use in relation to quality of life in patients with colorectal cancer: results from the FOCUS consortium. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1468-1481.	4.7	11
12	Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. <i>Current Opinion in Rheumatology</i> , 2021, 33, 292-299.	4.3	9
13	Response to Li and Hopper. <i>American Journal of Human Genetics</i> , 2021, 108, 527-529.	6.2	5
14	Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2021, 81, 2799-2802.	0.9	2
15	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3079-3093.	7.0	8
16	Postoperative Complications Are Associated with Long-Term Changes in the Gut Microbiota Following Colorectal Cancer Surgery. <i>Life</i> , 2021, 11, 246.	2.4	8
17	Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1106-1113.	2.5	1
18	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. <i>Cancers</i> , 2021, 13, 3817.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. <i>Cancer Causes and Control</i> , 2021, 32, 1375-1384.	1.8	3
20	<i>Fusobacterium nucleatum</i> and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. <i>Clinical Colorectal Cancer</i> , 2021, 20, e165-e172.	2.3	12
21	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. <i>Scientific Reports</i> , 2021, 11, 18156.	3.3	11
22	Determinants of Guideline-Discordant Breast Cancer Care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 61-70.	2.5	2
23	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 564-575.	2.5	10
24	Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 549-558.	2.5	7
25	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. <i>Nutrients</i> , 2021, 13, 4164.	4.1	3
26	Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. <i>Clinical Epigenetics</i> , 2020, 12, 5.	4.1	47
27	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	1.3	110
28	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. <i>Gastroenterology</i> , 2020, 158, 1300-1312.e20.	1.3	90
29	Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa051.	2.9	9
30	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 432-444.	6.2	124
31	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. <i>BMC Medicine</i> , 2020, 18, 229.	5.5	28
32	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. <i>BMC Medicine</i> , 2020, 18, 396.	5.5	76
33	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100010.	1.7	3
34	The Role of CT-Quantified Body Composition on Longitudinal Health-Related Quality of Life in Colorectal Cancer Patients: The Colocare Study. <i>Nutrients</i> , 2020, 12, 1247.	4.1	11
35	Risk factors for cancer-related distress in colorectal cancer survivors: one year post surgery. <i>Journal of Cancer Survivorship</i> , 2020, 14, 305-315.	2.9	17
36	Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 860-870.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. <i>Nature Communications</i> , 2020, 11, 597.	12.8	193
38	Associations between physical activity, sedentary behavior, and urinary oxidized guanine in colorectal cancer patients: results from the ColoCare Study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 1306-1309.	1.9	0
39	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 146-157.	6.3	129
40	Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15. <i>Aging Cell</i> , 2019, 18, e13013.	6.7	69
41	Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1802-1808.	2.5	20
42	Multiplatform Urinary Metabolomics Profiling to Discriminate Cachectic from Non-Cachectic Colorectal Cancer Patients: Pilot Results from the ColoCare Study. <i>Metabolites</i> , 2019, 9, 178.	2.9	10
43	Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. <i>Hormones and Cancer</i> , 2019, 10, 71-76.	4.9	9
44	Time to Follow-up After Colorectal Cancer Screening by Health Insurance Type. <i>American Journal of Preventive Medicine</i> , 2019, 56, e143-e152.	3.0	10
45	Obstetrical and infant outcomes among women with neoplasms during pregnancy. <i>Cancer Causes and Control</i> , 2019, 30, 651-661.	1.8	5
46	Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density. <i>JAMA Oncology</i> , 2019, 5, 635.	7.1	136
47	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. <i>Human Genetics</i> , 2019, 138, 307-326.	3.8	44
48	Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50-74 Years in a Screening Population. <i>Journal of Women's Health</i> , 2019, 28, 1051-1059.	3.3	10
49	Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma. <i>Cancer Causes and Control</i> , 2019, 30, 113-120.	1.8	5
50	The ColoCare Study: A Paradigm of Transdisciplinary Science in Colorectal Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 591-601.	2.5	48
51	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	21.4	377
52	Implications of Epigenetic Drift in Colorectal Neoplasia. <i>Cancer Research</i> , 2019, 79, 495-504.	0.9	26
53	Family History and Risk of Second Primary Breast Cancer after <i>In Situ</i> Breast Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 315-320.	2.5	12
54	Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results. <i>JAMA Oncology</i> , 2018, 4, 998.	7.1	20

#	ARTICLE	IF	CITATIONS
55	Alcohol, smoking, and risk of HER2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. <i>International Journal of Cancer</i> , 2018, 143, 1849-1857.	5.1	23
56	Rare loss of function variants in candidate genes and risk of colorectal cancer. <i>Human Genetics</i> , 2018, 137, 795-806.	3.8	10
57	Relationship Between Anthropometric Factors and Risk of Second Breast Cancer Among Women With a History of Ductal Carcinoma In Situ. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky020.	2.9	12
58	Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. <i>Cancer Epidemiology</i> , 2018, 56, 83-89.	1.9	4
59	Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years. <i>Hormones and Cancer</i> , 2017, 8, 211-218.	4.9	7
60	Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. <i>Cancer Research</i> , 2017, 77, 6033-6041.	0.9	33
61	Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 185-193.	2.5	34
62	Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 353-361.	329.8	49
63	Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1603-1610.	2.5	24
64	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 267-278.	3.6	14
65	Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity. <i>Journal of Proteome Research</i> , 2017, 16, 274-287.	3.7	8
66	Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. <i>Supportive Care in Cancer</i> , 2017, 25, 75-83.	2.2	36
67	Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 969-978.	0.9	15
68	Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1268-1273.	2.5	17
69	Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 545-554.	2.5	64
70	Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1297-1304.	2.5	33
71	Resource utilization after implementing a hospital-wide standardized feeding tube placement pathway. <i>Journal of Pediatric Surgery</i> , 2016, 51, 1674-1679.	1.6	25
72	Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?. <i>Clinical Chemistry</i> , 2016, 62, 737-742.	3.2	61

#	ARTICLE	IF	CITATIONS
73	Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. <i>Gynecologic Oncology</i> , 2016, 140, 138-144.	1.4	56
74	Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 944-950.	2.5	41
75	Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1666-1672.	2.5	122
76	Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1423-1426.	2.5	8
77	Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1764-1771.	7.0	42
78	Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 445-454.	2.5	25
79	Breastfeeding and Triple-Negative Breast Cancer: Potential Implications for Racial/Ethnic Disparities. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	12
80	Antihypertensive Medications and Breast Cancer Risk—Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 641.	5.1	0
81	Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. <i>Cancer</i> , 2014, 120, 1026-1034.	4.1	48
82	US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	969
83	Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. <i>Cancer Research</i> , 2014, 74, 4078-4089.	0.9	74
84	Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2181-2185.	2.5	10
85	Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 439-447.	2.5	8
86	Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 481-489.	2.5	21
87	Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. <i>JAMA Internal Medicine</i> , 2013, 173, 1629.	5.1	110
88	Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 579-587.	2.5	101
89	Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. <i>Cancer Research</i> , 2012, 72, 2028-2035.	0.9	67
90	Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. <i>Cancer Prevention Research</i> , 2012, 5, 1036-1043.	1.5	57

#	ARTICLE	IF	CITATIONS
91	Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. Breast Cancer Research and Treatment, 2012, 134, 1297-1304.	2.5	64
92	Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study. Breast Cancer Research and Treatment, 2012, 135, 611-618.	2.5	20
93	Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 2012, 131, 607-617.	2.5	69
94	Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 470-477.	6.3	190
95	Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Research and Treatment, 2011, 125, 545-551.	2.5	17
96	Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Research and Treatment, 2011, 127, 729-738.	2.5	245
97	Discovery and Validation of Breast Cancer Early Detection Biomarkers in Preclinical Samples. Hormones and Cancer, 2011, 2, 125-131.	4.9	7
98	Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 1752-1760.	6.3	25
99	Trends in Distant-Stage Breast, Colorectal, and Prostate Cancer Incidence Rates from 1992 to 2004: Potential Influences of Screening and Hormonal Factors. Hormones and Cancer, 2010, 1, 55-62.	4.9	5
100	Risk of Mortality by Histologic Type of Breast Cancer in the United States. Hormones and Cancer, 2010, 1, 156-165.	4.9	42
101	Relationship between Radiation Exposure and Risk of Second Primary Cancers among Atomic Bomb Survivors. Cancer Research, 2010, 70, 7187-7198.	0.9	41
102	Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. Journal of the National Cancer Institute, 2010, 102, 1422-1431.	6.3	121
103	Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1643-1654.	2.5	43
104	Breast Cancer Biology and Clinical Characteristics. , 2010, , 21-46.		11
105	Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users. Cancer Research, 2010, 70, 8598-8606.	0.9	37
106	Exogenous Hormones. , 2010, , 89-117.		1
107	Endogenous Hormones. , 2010, , 73-87.		0
108	Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk. American Journal of Epidemiology, 2009, 170, 1241-1249.	3.4	19



#	ARTICLE	IF	CITATIONS
109	Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Positive Specific Subtypes of Contralateral Breast Cancer. <i>Cancer Research</i> , 2009, 69, 6865-6870.	0.9	37
110	Relationship between Migraine History and Breast Cancer Risk among Premenopausal and Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2030-2034.	2.5	29
111	Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor-Positive Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5312-5318.	1.6	117
112	Reply to reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer. <i>Cancer</i> , 2009, 115, 1803-1803.	4.1	1
113	Genetic Polymorphisms in the Catechol Estrogen Metabolism Pathway and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1461-1467.	2.5	40
114	Reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer. <i>Cancer</i> , 2008, 113, 1521-1526.	4.1	114
115	Migraine in Postmenopausal Women and the Risk of Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3116-3122.	2.5	38
116	Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2078-2086.	2.5	101
117	Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 43-50.	2.5	70
118	Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2773-2780.	2.5	93
119	Relationship between Age Maximum Height Is Attained, Age at Menarche, and Age at First Full-Term Birth and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2144-2149.	2.5	45
120	Timing of Menarche and First Full-Term Birth in Relation to Breast Cancer Risk. <i>American Journal of Epidemiology</i> , 2007, 167, 230-239.	3.4	83
121	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. <i>Breast Cancer Research</i> , 2007, 9, R6.	5.0	576
122	Antidepressant use and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 131-140.	2.5	44
123	Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States). <i>Cancer Causes and Control</i> , 2006, 17, 695-703.	1.8	49
124	Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. <i>Cancer</i> , 2006, 106, 2104-2112.	4.1	167
125	Pathologic, Clinical, and Epidemiologic Characteristics of Invasive Lobular Breast Carcinoma and a Review of Studies Evaluating its Association with Hormone Replacement Therapy. , 2005, , 47-64.		0
126	The Relationship Between Various Measures of Cigarette Smoking and Risk of Breast Cancer Among Older Women 65-79 years of Age (United States). <i>Cancer Causes and Control</i> , 2005, 16, 975-985.	1.8	39



#	ARTICLE	IF	CITATIONS
127	Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1008-1011.	2.5	126
128	Racial and ethnic disparities in breast cancer stage, treatment, and survival in the United States. <i>Ethnicity and Disease</i> , 2005, 15, S5-9.	2.3	35
129	Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes. <i>Cancer Research</i> , 2004, 64, 8541-8549.	0.9	197
130	Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. <i>Maturitas</i> , 2004, 49, 44-50.	2.4	13
131	Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. <i>Cancer</i> , 2003, 98, 1504-1513.	4.1	131
132	Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. <i>International Journal of Cancer</i> , 2003, 107, 647-651.	5.1	51
133	Birthweight and risk of overall and cause-specific childhood mortality. <i>Paediatric and Perinatal Epidemiology</i> , 2003, 17, 164-170.	1.7	29
134	Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998. <i>Journal of Clinical Oncology</i> , 2003, 21, 28-34.	1.6	220
135	Risk of Mortality by Histologic Type of Breast Cancer Among Women Aged 50 to 79 Years. <i>Archives of Internal Medicine</i> , 2003, 163, 2149.	3.8	87
136	Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1421.	7.4	434
137	Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 3254.	7.4	346
138	Differences in Breast Cancer Stage, Treatment, and Survival by Race and Ethnicity. <i>Archives of Internal Medicine</i> , 2003, 163, 49.	3.8	576
139	The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1061-6.	2.5	23
140	Changing Incidence of Lobular Carcinoma in situ of the Breast. <i>Breast Cancer Research and Treatment</i> , 2002, 75, 259-268.	2.5	94
141	Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 601-7.	2.5	96
142	Changing incidence rate of invasive lobular breast carcinoma among older women. <i>Cancer</i> , 2000, 88, 2561-2569.	4.1	138
143	Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. <i>Cancer</i> , 2000, 88, 2570-2577.	4.1	179
144	Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. , 2000, 88, 2570.		2

#	ARTICLE	IF	CITATIONS
145	Changing incidence rate of invasive lobular breast carcinoma among older women. <i>Cancer</i> , 2000, 88, 2561-2569.	4.1	3